Table 3 Geometric mean concentrations (GMC) and 95% confidence intervals (CI) for type-specific human papillomavirus (HPV) immunoglobulin G antibodies following receipt of nine-valent HPV vaccine among Alaska Native children
Type | 6 months after dose 1 [N = 205] | 1 month after dose 2 [N = 197] | 1 year after dose 2 [N = 172] | 3 years after dose 2 [N = 145] | ||||
|---|---|---|---|---|---|---|---|---|
| Â | GMCa | (95% CI) | GMCa | (95% CI) | GMCa | (95% CI) | GMCa | (95% CI) |
HPV 6 | 59 | (52–67) | 4,535 | (4,067–5,056) | 469 | (396–555) | 220 | (183–263) |
HPV 11 | 42 | (37–48) | 3,727 | (3,390–4,097) | 374 | (324–432) | 171 | (146–200) |
HPV 16 | 22 | (20–25) | 1,781 | (1,610–1,969) | 219 | (188–254) | 94 | (80–111) |
HPV 18 | 13 | (12–15) | 635 | (566–713) | 62 | (52–76) | 27 | (23–32) |
HPV 31 | 26 | (23–28) | 1,554 | (1,416–1,704) | 176 | (151–205) | 88 | (76–102) |
HPV 33 | 36 | (32–39) | 2,540 | (2,275–2,836) | 274 | (230–326) | 123 | (103–148) |
HPV 45 | 8 | (7–9) | 462 | (408–522) | 45 | (37–54) | 25 | (21–30) |
HPV 52 | 96 | (85–109) | 2,960 | (2,686–3,261) | 368 | (314–431) | 184 | (158–214) |
HPV 58 | 93 | (85–102) | 3,483 | (3,162–3,838) | 435 | (375–504) | 207 | (176–245) |